Medicare finalizes restrictions on new Alzheimer’s drug, despite pressure from drugmakers Medicare finalized its decision to restrict coverage for Aduhelm to patients participating in clinical trials, marking the end of an intense pressure campaign from drugmakers and some patient groups who wanted Medicare to reverse its initial proposal and pay for the drug for more patients. Read more If you’d like to stop receiving these alerts, click on the "update email preferences" link below. | 
No comments